SUPN SUPERNUS PHARMACEUTICALS, INC.

8-K Current Report

Filed: February 24, 2026

Health Care

Pharmaceutical Preparations

SUPERNUS PHARMACEUTICALS, INC. (SUPN) 8-K current report filed with SEC EDGAR on February 24, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 5.02: Departure/Election of Directors or Officers

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

• CEO Khattar base salary raised 3% to $1,067,100; 2025 bonus $846,930; granted 341,610 options + 204,966 PSUs
• CFO Dec salary raised ~4% to $525,100; 2025 bonus $233,894; granted 17,500 options, 3,000 RSUs, 3,500 PSUs

+3 more insights

Other SUPERNUS PHARMACEUTICALS, INC. 8-K Filings

8-K Feb 24, 2026

Get deeper insights on SUPERNUS PHARMACEUTICALS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.